ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PIPE latest financing SEC

<< Previous

Bullboard Posts

Next >>

Comment by goldtechon Sep 03, 2023 2:49pm

107 Views

Post# 35618187

RE:RE:RE:PIPE latest financing SEC

You are correct M101 and you should if not already ahve done file a complaint with the SEC and let them investigate how you can sell over 13 million shares on one day when there is not even that many outstanding.

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs